Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma

BMC Cancer
K LisenkoM Witzens-Harig

Abstract

The addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) -like therapy has improved survival in primary mediastinal B-cell lymphoma (PMBCL) patients. However, these results were obtained in young low risk patients and a reevaluation in an unselected patient cohort is warranted. In this study, we analyzed 80 PMBCL patients treated with a CHOP-based regimen with and without rituximab. In the non-rituximab cohort 10-year progression free survival (PFS) was 67% and 10-year overall survival (OS) was 72% versus a PFS of 95% and a OS of 92% in the rituximab group, PFS P = 0.001, OS P = 0.023. A subgroup PFS analysis by international prognostic index (IPI) risk revealed that all risk groups benefit from addition of rituximab to induction chemotherapy. In addition, OS probability was higher in the group of non-low risk patients who were treated with rituximab compared to those patients who did not receive rituximab (P = 0.035). In multivariate analysis, only addition of rituximab to induction chemotherapy and reaching complete remission (CR) after first line therapy had a beneficial effect on both PFS and OS, whereas IPI, age, upfront high dose (HD) chemotherapy/autologous blood stem cell transpl...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M LazzarinoP Möller
Nov 18, 1998·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M P MartelliF Mandelli
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A A Abou-ElellaJ O Armitage
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·B D ChesonG P Canellos
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P C BishopP C Elwood
Aug 21, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M RiegerUNKNOWN MabThera International Trial (MInT) Group
Apr 12, 2013·The New England Journal of Medicine·Kieron DunleavyWyndham H Wilson
Jul 19, 2013·The New England Journal of Medicine·Wyndham H WilsonKieron Dunleavy
Jul 19, 2013·The New England Journal of Medicine·Amanda F CashenNancy L Bartlett
Apr 29, 2015·Cancer Treatment Reviews·Vijaya Raj BhattJames O Armitage

❮ Previous
Next ❯

Software Mentioned

R
R Development Core Team

Related Concepts

Related Feeds

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.